Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL5782423 | 0.90 | KMT2A (0.51) | KMT2AMEN1ALDH1A1MAPKAPK2MAPK1 | |
| SCHEMBL5780432 | 0.78 | RXFP1 (0.52) | KMT2AMEN1MAPTRXFP1MAPK1 | |
| SCHEMBL5756770 | 0.76 | KDM4E (0.53) | KMT2AMEN1RXFP1ALDH1A1MAPK1 | |
| SCHEMBL6992541 | 0.75 | KMT2A (0.43) | KMT2AMEN1MAPTRXFP1ALDH1A1 | |
| SCHEMBL21133083 | 0.74 | KCNK3 (0.86) | KMT2AMEN1MAPTRXFP1KCNK3 | |
| SCHEMBL5758311 | 0.72 | LMNA (0.47) | KMT2AMEN1RXFP1MAPK1 | |
| SCHEMBL17025452 | 0.71 | KDM4E (0.49) | KMT2AMEN1RXFP1ALDH1A1MAPK1 | |
| SCHEMBL1538310 | 0.70 | MEN1 (0.59) | KMT2AMEN1RXFP1MAPK1KDM4E | |
| SCHEMBL27306759 | 0.70 | PTGS2 (0.68) | KMT2AMEN1MAPTKCNK3ALDH1A1 | |
| SCHEMBL7271928 | 0.69 | CNR2 (0.60) | KMT2AMEN1MAPTKCNK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129356-B2 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-31 | — | — | US | disclosed |
| EP-1347966-B1 | FARNESYL TRANSFERASE INHIBITING 4-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2006-03-08 | — | — | EP | disclosed |
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063944-A1 | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives | FNTA, FNTB, CYP7A1 | KMT2A 2487/4885MEN1 1707/4885MAPT 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.